MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317888 | Name: Fluocinonide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluocinonide is a potent glucocorticoid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort. Fluocinonide ranks as a "high-potency" (second-highest rank) topical corticosteroid. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis (HPA) suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Chemical Structure

Fluocinonide
Fluocinonide
CAS#356-12-7

Theoretical Analysis

MedKoo Cat#: 317888

Name: Fluocinonide

CAS#: 356-12-7

Chemical Formula: C26H32F2O7

Exact Mass: 494.2116

Molecular Weight: 494.52

Elemental Analysis: C, 63.15; H, 6.52; F, 7.68; O, 22.65

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
25mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Fluocinonide, Fluocinolide; Fluocinolone acetonide acetate; Vanos; Lidex; Lyderm; Metosyn; Topsyn; Lonide; NSC 101791; NSC101791; NSC-101791
IUPAC/Chemical Name
2-((2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-6a,8a,10,10-tetramethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl acetate
InChi Key
WJOHZNCJWYWUJD-IUGZLZTKSA-N
InChi Code
InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
SMILES Code
CC(OCC([C@@]12OC(C)(C)O[C@]1([H])C[C@@]3([H])[C@@](C[C@H](F)C4=CC(C=C[C@@]45C)=O)([H])[C@]5(F)[C@@H](O)C[C@@]32C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 494.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hix E, Gustafson CJ, O'Neill JL, Huang K, Sandoval LF, Harrison J, Clark A, Feldman SR. Adherence to a five day treatment course of topical fluocinonide 0.1% cream in atopic dermatitis. Dermatol Online J. 2013 Oct 16;19(10):20029. PubMed PMID: 24139369. 2: Woods MT, Brown PA, Baig-Lewis SF, Simpson EL. Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. J Drugs Dermatol. 2011 Feb;10(2):171-6. PubMed PMID: 21283922; PubMed Central PMCID: PMC3156681. 3: Yentzer BA, Ade RA, Fountain JM, Clark AR, Taylor SL, Borgerding E, Feldman SR. Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis. Cutis. 2010 Oct;86(4):208-13. PubMed PMID: 21140931. 4: Del Rosso JQ, Bhambri S. Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol. 2009 Sep;2(9):24-32. PubMed PMID: 20729956; PubMed Central PMCID: PMC2923967. 5: Lee CS, Koo J. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison. J Drugs Dermatol. 2009 Aug;8(8):751-5. PubMed PMID: 19663113. 6: Kosari P, Feldman SR. Case report: Fluocinonide-induced perioral dermatitis in a patient with psoriasis. Dermatol Online J. 2009 Mar 15;15(3):15. PubMed PMID: 19379659. 7: Uliasz A, Zeichner J, Soung J, Wong V, Lebwohl M. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses. Cutis. 2008 Jun;81(6):517-9. PubMed PMID: 18666395. 8: Schlessinger J, Miller B, Gilbert RD, Plott RT; Vanos Study Group. An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. Arch Dermatol. 2006 Dec;142(12):1568-72. PubMed PMID: 17178982. 9: Miura Y, Hata M, Yuge M, Numano K, Iwakiri K. Allergic contact dermatitis from 1,2,6-hexanetriol in fluocinonide cream. Contact Dermatitis. 1999 Aug;41(2):118-9. PubMed PMID: 10445708. 10: Carbone M, Conrotto D, Carrozzo M, Broccoletti R, Gandolfo S, Scully C. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Dis. 1999 Jan;5(1):44-9. PubMed PMID: 10218041. 11: Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, Lowe NJ, Phillips TJ, Rosen T, Wolf DI, Quell JM, Sefton J, Lue JC, Gibson JR, Chandraratna RA. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998 May;38(5 Pt 1):705-11. PubMed PMID: 9591815. 12: Carbone M, Carrozzo M, Broccoletti R, Mattea A, Gandolfo S. [The topical treatment of atrophic-erosive oral lichen planus with fluocinonide in a bioadhesive gel, chlorhexidine and miconazole gel. A totally open trial]. Minerva Stomatol. 1996 Mar;45(3):61-8. Italian. PubMed PMID: 8926975. 13: Calobrisi SD, Mutasim DF, McDonald JS. Pyostomatitis vegetans associated with ulcerative colitis. Temporary clearance with fluocinonide gel and complete remission after colectomy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Apr;79(4):452-4. PubMed PMID: 7614204. 14: Agbaba D, Zivanov-Stakić D, Vladimirov S, Zubac K. Determination of triamcinolone, triamcinolone acetonide and fluocinonide in dosage forms. Acta Pol Pharm. 1990;47(1-2):15-7. PubMed PMID: 12959252. 15: Bickers D, Cornell R, Kamm AR, Bauman WE, Handler RM, Medansky RS, Sturm HM. Clobetasol propionate ointment once daily versus fluocinonide ointment three times daily in psoriasis. Int J Dermatol. 1988 Jan-Feb;27(1):54-5. PubMed PMID: 3278991. 16: Willis I, Cornell RC, Penneys NS, Zaias N. Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clin Ther. 1986;8(3):275-82. PubMed PMID: 3521856. 17: Jegasothy B, Jacobson C, Levine N, Millikan L, Olsen E, Pinnell S, Cole G, Weinstein G, Porter M. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol. 1985 Sep;24(7):461-5. PubMed PMID: 3902682. 18: Senter TP. Topical fluocinonide and tachyphylaxis. Arch Dermatol. 1983 May;119(5):363-4. PubMed PMID: 6847210. 19: Pimlott SJ, Walker DM. A controlled clinical trial of the efficacy of topically applied fluocinonide in the treatment of recurrent aphthous ulceration. Br Dent J. 1983 Mar 19;154(6):174-7. PubMed PMID: 6342633. 20: Engel MF. Treatment of psoriasis with amcinonide 0.1 percent and fluocinonide 0.05 percent ointments. A comparative double-blind study. Cutis. 1982 Jun;29(6):646-50. PubMed PMID: 7049592.